Cytek Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

FREMONT, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cytek

 Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the fourth quarter and year ended December 31, 2025.

Fourth Quarter and Full Year 2025 Highlights

• Total revenue for the fourth quarter was $62.1 million, an 8% increase compared to the fourth quarter of 2024, and the highest quarterly revenue achieved historically at Cytek
  
  
• Total revenue for the full year 2025 was $201.5 million, a 1% increase compared to the full year 2024
  
  
• Total recurring revenue, comprised of service and reagent revenues, grew 21% in 2025 compared to 2024, reaching 34% of total revenue
  
  
• Adjusted EBITDA in the year ended December 31, 2025 was $5.0 million, compared to $22.4 million for the full year 2024
  
  
• Expanded to a total installed base of 3,664 Cytek instruments, with 630 total instruments placed during 2025. Unit placements of Cytek’s Aurora CS system grew 22% in 2025 over the prior year.
  
  
• Launched the Cytek Aurora™ Evo system, a new full spectrum flow cytometer that improves on Cytek’s flagship Aurora system and offers faster sample throughput, automated instrument startup and shutdown, enhanced resolution for small particle detection, and data harmonization
  
  
• Launched the Cytek
  ®
   Muse
  ® 
  Micro cell analyzer, which was awarded the 2025 Biotech Breakthrough Award for Drug Discovery Solution of the Year and highlights Cytek’s commitment to making cell analysis accessible, intuitive and cost-effective for laboratories of all sizes
  
  

“We were pleased by our fourth quarter revenue growth, which marked a clear acceleration versus the prior year and a continuation of the positive trends we saw earlier in 2025. Our revenue performance in the quarter was driven by strong momentum in FSP instrument sales in all major markets worldwide alongside sustained growth in our recurring revenue streams. We were especially encouraged to see improving instrument demand in both the US and EMEA,” said Dr. Wenbin Jiang, CEO of Cytek Biosciences. “This broad-based execution positions us well for 2026, where our priorities will continue to focus on the growth of our high-margin recurring revenue lines, accelerating the adoption of our instrument platforms, advancing a pipeline of innovative new products, and delivering profitable, durable growth in the large cell analysis market.”

Fourth Quarter 2025 Financial Results

Total revenue for the fourth quarter of 2025 was $62.1 million, an 8% increase compared to the fourth quarter of 2024. The increase in revenue was due to higher revenue broadly across all major regions.

GAAP gross profit was $32.9 million for the fourth quarter of 2025, a 2% decrease compared to the fourth quarter of 2024. GAAP gross profit margin was 53% in the fourth quarter of 2025 compared to 59% in the fourth quarter of 2024. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 55% in the fourth quarter of 2025, compared to 61% in the fourth quarter of 2024.

Operating expenses were $38.5 million for the fourth quarter of 2025, an increase of $7.8 million or 25.5% compared to the fourth quarter of 2024 due to increased general and administrative and sales and marketing expenses, and a non-recurring benefit of $2.6 million in the prior year quarter, offset by a reduction in research and development expenses.

Research and development expenses were $9.0 million for the fourth quarter of 2025, a 7.8% decrease compared to the fourth quarter of 2024.

Sales and marketing expenses were $13.1 million for the fourth quarter of 2025, a 10.6% increase compared to the fourth quarter of 2024.

General and administrative expenses were $16.4 million for the fourth quarter of 2025, increasing $7.3 million compared to the fourth quarter of 2024 due primarily to increased headcount, sales commission, and litigation-related expenses, and a non-recurring benefit of $2.6 million in the prior-year quarter related to a change in estimate of an adjustment to a license and royalty settlement liability.

Loss from operations in the fourth quarter of 2025 was $5.6 million compared to income from operations of $3.0 million in the fourth quarter of 2024. Net loss in the fourth quarter of 2025 was $44.1 million, compared to a net income of $9.6 million in the fourth quarter of 2024. The net loss in the fourth quarter of 2025 is primarily due to the recording of a non-cash valuation allowance against deferred tax assets of $38.1 million due to the uncertainty of realizing the associated future tax benefits, and the $5.6 million loss from operations.

Adjusted EBITDA in the fourth quarter of 2025, after adjusting for stock-based compensation expense and foreign currency exchange impacts, declined to $4.5 million compared to $12.5 million in the fourth quarter of 2024, primarily due to the $7.8 million increase in operating expenses. Excluding investment income, Adjusted EBITDA for the fourth quarter was $2.7 million, compared to $10.2 million in the fourth quarter of 2024.

Cash and marketable securities totaled $261.5 million as of December 31, 2025, compared to $261.7 million as of September 30, 2025, a decrease of $0.2 million.

Full Year 2025 Financial Results 

Total revenue for the year ended December 31, 2025 was $201.5 million, a 1% increase compared to the year ended December 31, 2024. The increase in revenue was due to higher revenue in APAC and the US, partially offset by softness in EMEA, and rest-of-world. On a non-GAAP constant currency basis, full year 2025 revenue was $198.2 million, a decline of 1.1% compared to full year 2024 as reported.

GAAP gross profit was $104.5 million for the year ended December 31, 2025, a 6% decrease compared to the year ended December 31, 2024. GAAP gross profit margin was 52% for the year ended December 31, 2025 compared to 55% in the year ended December 31, 2024. Adjusted gross profit margin, after adjusting for stock-based compensation expense and amortization of acquisition-related intangibles, was 55% for the year ended December 31, 2025 compared to 59% in the year ended December 31, 2024.

Operating expenses were $144.8 million for the year ended December 31, 2025, a 10% increase compared to the year ended December 31, 2024, primarily due to higher general and administrative expense, partially offset by lower research and development expense.

Research and development expenses were $36.5 million for the year ended December 31, 2025, a 7.4% decrease compared to the year ended December 31, 2024. 

Sales and marketing expenses were $49.4 million for the year ended December 31, 2025, a 0.7% increase compared to the year ended December 31, 2024. 

General and administrative expenses were $58.9 million for the year ended December 31, 2025, increasing 36.7% compared to the year ended December 31, 2024, due primarily to higher patent litigation expenses, higher compensation, sales and use tax, and software expenses and a lower benefit related to the change in estimate of an adjustment to a license and royalty settlement liability.

Loss from operations for the year ended December 31, 2025 was $40.4 million compared to loss from operations of $20.5 million for the year ended December 31, 2024. Net loss for the year ended December 31, 2025 was $66.5 million compared to a net loss of $6.0 million for the year ended December 31, 2024. The increase in net loss in full year 2025 is primarily driven by a $6.6 million decline in gross profit; a $5.7 million reduction in interest expense, primarily due to a non-recurring benefit in the prior year related to the change in estimate of an adjustment to a license and royalty settlement liability; a $36.4 million increase in tax expense primarily due to the recording of a non-cash valuation allowance against deferred tax assets of $33.1 million; and a $13.2 million increase in operating expenses.

Adjusted EBITDA for the year ended December 31, 2025, after adjusting for stock-based compensation expense and foreign currency impacts was $5.0 million, compared to $22.4 million for the year ended December 31, 2024, primarily due to $6.6 million lower gross profit and $13.2 million higher operating expenses. Excluding investment income, Adjusted EBITDA for the year ended December 31, 2025 was $(3.1) million, compared to $14.4 million for the year ended December 31, 2024.

Cash and marketable securities totaled $261.5 million as of December 31, 2025 compared to $277.9 million as of December 31, 2024, a decrease of $16.4 million. The reduction in cash and marketable securities was primarily due to the Company’s repurchase of approximately 3.3 million shares for $15.1 million during 2025.

2026 Revenue Outlook

Cytek Biosciences initiates its 2026 revenue guidance for full year 2026 revenue to be in the range of $205 million to $212 million, representing growth of 2% to 5% over full year 2025, assuming no change in current foreign currency exchange rates or 2025 US tariff policy.

Webcast Information

Cytek will host a conference call to discuss its fourth quarter and year end 2025 financial results on Thursday, February 26, 2026, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

About Cytek Biosciences, Inc.

Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP

) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek’s platform includes: its core FSP instruments, the Cytek Aurora™, Northern Lights™, Cytek Aurora™ CS and Cytek Aurora™ Evo systems; the Muse Micro system; the Cytek Orion™ reagent cocktail preparation system; the Enhanced Small Particle™ (ESP™) detection technology; the flow cytometers and imaging products under the Amnis  and Guava  brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

Cytek’s products are for research use only and not for use in diagnostic procedures (other than Cytek’s Northern Lights-CLC system and certain reagents, which are available for clinical use only in China and the European Union).

Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Enhanced Small Particle, ESP, Muse, Cytek Orion, Amnis and Guava are trademarks of Cytek Biosciences, Inc.

In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website as a channel of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek’s website in addition to following its SEC filings, news releases, public conference calls and webcasts.

Statement Regarding Use of Non-GAAP Financial Information

Cytek has presented certain financial information in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”) and also on a non-GAAP basis for the three-month period and full year ended December 31, 2025 and December 31, 2024. Management believes that non-GAAP financial measures, including “Adjusted gross profit,” “Adjusted gross profit margin,” “Adjusted EBITDA,” “Adjusted EBITDA excluding investment income,” and revenue on a “constant currency basis,” referenced in this release, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Cytek encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.

Cytek Biosciences, Inc. Consolidated Balance Sheets (Unaudited)
(In thousands, except share and per share data)		December 31, 2025				December 31, 2024
Assets
Current assets:
Cash and cash equivalents		$	90,853			$	98,716
Restricted cash			—				29
Marketable securities			170,676				179,145
Trade accounts receivable, net			62,509				60,588
Inventories			48,428				43,893
Prepaid expenses and other current assets			19,530				14,075
Total current assets			391,996				396,446
Deferred income tax assets, noncurrent			—				33,374
Property and equipment, net			18,009				17,962
Operating lease right-of-use assets			11,315				10,168
Goodwill			16,697				16,663
Intangible assets, net			16,821				20,128
Other noncurrent assets			6,704				4,759
Total assets		$	461,542			$	499,500
Liabilities and stockholders’ equity
Current liabilities:
Trade accounts payable		$	6,410			$	5,529
Legal settlement liability, current			2,495				1,705
Accrued expenses			23,417				21,443
Other current liabilities			16,978				13,494
Deferred revenue, current			28,504				25,492
Total current liabilities			77,804				67,663
Legal settlement liability, noncurrent			6,786				9,036
Deferred revenue, noncurrent			18,339				16,098
Operating lease liability, noncurrent			14,042				7,552
Long term debt			525				1,050
Other noncurrent liabilities			2,307				2,364
Total liabilities		$	119,803			$	103,763
Stockholders’ equity:
Common stock, $0.001 par value; 1,000,000,000 authorized shares as of December 31, 2025 and December 31, 2024, respectively; 128,550,136 and 129,205,901 issued and outstanding shares as of December 31, 2025 and December 31, 2024, respectively.			129				129
Additional paid-in capital			441,107				430,791
Accumulated deficit			(101,738	)			(35,199	)
Accumulated other comprehensive income			2,241				16
Total stockholders’ equity			341,739				395,737
Total liabilities and stockholders’ equity		$	461,542			$	499,500

Cytek Biosciences, Inc. Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
		Three Months Ended December 31,								Twelve Months Ended December 31,
(In thousands, except share and per share data)			2025				2024				2025				2024
Revenue, net:
Product		$	46,594			$	45,021			$	144,233			$	153,263
Service		$	15,547			$	12,455			$	57,260			$	47,190
Total revenue, net		$	62,141			$	57,476			$	201,493				200,453
Cost of sales:
Product			21,635				19,044				69,813				69,088
Service			7,621				4,780				27,220				20,259
Total cost of sales			29,256				23,824				97,033				89,347
Gross profit			32,885				33,652				104,460				111,106
Operating expenses:
Research and development			8,962				9,723				36,468				39,402
Sales and marketing			13,131				11,874				49,440				49,114
General and administrative			16,386				9,069				58,936				43,113
Total operating expenses			38,479				30,666				144,844				131,629
(Loss) income from operations			(5,594	)			2,986				(40,384	)			(20,523	)
Other income (expense):
Interest income (expense), net			725				5,933				(474	)			5,239
Interest income			580				913				2,216				5,121
Other income, net			258				491				8,801				4,463
Total other income, net			1,563				7,337				10,543				14,823
(Loss) income before income taxes			(4,031	)			10,323				(29,841	)			(5,700	)
Provision for (benefit from) income taxes			40,045				680				36,698				320
Net (loss) income		$	(44,076	)		$	9,643			$	(66,539	)		$	(6,020	)
Less: net (loss) income allocated to noncontrolling interests			—				—				—				—
Net (loss) income attributable to common stockholders, basic and diluted		$	(44,076	)		$	9,643			$	(66,539	)		$	(6,020	)
Net (loss) income attributable to common stockholders per share, basic		$	(0.34	)		$	0.07			$	(0.52	)		$	(0.05	)
Net (loss) income attributable to common stockholders per share, diluted		$	(0.34	)		$	0.07			$	(0.52	)		$	(0.05	)
Weighted-average shares used in calculating net (loss) income per share, basic			128,166,224				129,090,641				127,745,939				130,611,330
Weighted-average shares used in calculating net (loss) income per share, diluted			128,166,224				130,860,114				127,745,939				130,611,330
Comprehensive (loss) income:															—
Net (loss) income		$	(44,076	)		$	9,643			$	(66,539	)		$	(6,020	)
Foreign currency translation adjustment, net of tax			1,383				(39	)			2,167				1,193
Unrealized gain (loss) on marketable securities			38				(47	)			58				97
Net comprehensive (loss) income		$	(42,655	)		$	9,557			$	(64,314	)		$	(4,730	)

Cytek Biosciences, Inc. Reconciliation of GAAP to Non-GAAP Measures (Unaudited)
		Three months ended								Twelve months ended
(In thousands)		December 31, 2025				December 31, 2024				December 31, 2025				December 31, 2024
GAAP gross profit		$	32,885			$	33,652			$	104,460			$	111,106
Stock based compensation		$	893			$	1,139			$	3,995			$	4,438
Amortization of acquisition-related intangible assets		$	481			$	498			$	1,935			$	1,997
Non-GAAP adjusted gross profit		$	34,259			$	35,289			$	110,390			$	117,541
GAAP gross margin			53	%			59	%			52	%			55	%
Non-GAAP adjusted gross margin			55	%			61	%			55	%			59	%
GAAP net income		$	(44,076	)		$	9,643			$	(66,539	)		$	(6,020	)
Depreciation and amortization		$	3,045			$	2,849			$	11,978			$	10,595
Provision for income taxes*		$	40,045			$	680			$	36,698			$	320
Interest income		$	(580	)		$	(913	)		$	(2,215	)		$	(5,121	)
Interest (income) expense, net		$	(725	)		$	(5,933	)		$	475			$	(5,240	)
Foreign currency exchange gain (loss)		$	1,255			$	1,764			$	(730	)		$	3,597
Stock based compensation		$	5,527			$	7,003			$	24,585			$	26,848
License and royalty settlement adjustment		$	—			$	(2,561	)		$	—			$	(2,561	)
Non-recurring deferred ATM facility offering cost write off		$	—			$	—			$	711			$	—
Non-GAAP adjusted EBITDA		$	4,491			$	12,532			$	4,963			$	22,418
Investment income		$	(1,805	)		$	(2,298	)		$	(8,075	)		$	(8,016	)
Non-GAAP adjusted EBITDA excluding investment income		$	2,686			$	10,234			$	(3,112	)		$	14,402

*The Company recorded valuation allowance of $38.1 million and $33.1 million for the three and twelve months ended December 31, 2025, respectively, due to cumulative pre-tax losses and uncertainty regarding the realization of deferred tax assets. The increase was recorded as a component of income tax expense.

Revenue		Three months ended December 31, 2025			Three months ended December 31, 2024			Twelve months ended December 31, 2025			Twelve months ended December 31, 2024
		Unaudited			Unaudited			Unaudited			Unaudited
As reported		62,141			57,476			201,493			200,453
Non-GAAP constant currency		60,161			58,590			198,247			201,346
FX Impact [$]		(1,980	)		1,114			(3,246	)		893
FX Impact [%]		(3.2	)%		1.9	%		(1.6	)%		0.4	%

*Revenue in Constant Currency. The Company defines revenue in constant currency as GAAP revenue adjusted for revenue reported in currencies other than United States dollars as if they were converted into United States dollars using the average exchange rates from the comparative period rather than the actual exchange rates in effect during the respective periods. The Company provides revenue in constant currency information as a framework for assessing how its underlying businesses performed period to period, excluding the effects of foreign currency fluctuations.